2.GLP-1受体激动剂，何时用？用多久（城市会）.ppt

* 更令人兴奋的发现是，对糖尿病小鼠模型进行同源胰岛移植，48小时后检测移植的胰岛β细胞凋亡情况，结果发现利拉鲁肽治疗小鼠β细胞凋亡显著减少。提示利拉鲁肽能抑制胰岛β细胞凋亡。 西罗莫司：一种免疫抑制剂，具有beta细胞毒性。 FIG. 3. Proliferation and apoptosis of -cells after islet transplantation. Islet grafts procured 2 wk or 48 h after transplantation (n=5 per treatment group and time point) were stained for immunofluorescence microscopy. Insulin (green) and BrdU incorporation (red) (A) or insulin (red) and TUNEL (green) (B), respectively. Representative samples are shown in A and B, whereas summative tabulations from all samples (a minimum of 100 insulin staining cells per sample) are shown graphically in C and D, respectively. Photomicrographs were taken using a 10 x objective lens. Asterisks (*, **) indicate statistically significant (P0.05) when compared by ANOVA and post hoc test with the corresponding nonliraglutide-treated control groups. * Once-daily injection covers 24 hours in type 2 diabetes The sustained blood glucose lowering action of liraglutide was demonstrated in this study of 13 patients with type 2 diabetes. Patients received 1 week of once-daily subcutaneous liraglutide injections (6 μg/kg) and 1 week of once-daily placebo injections in a double-blind, crossover design. Previous OAD agents were discontinued 2 weeks prior to the study treatment period. Following liraglutide treatment, plasma glucose was consistently lower during a 24-hour test period than following placebo treatment. This observation was borne out statistically in an assessment of area under the curve (AUC; mmol/L/h) for this 24-hour test period (187.5 vs. 232.3, for liraglutide and placebo, respectively, p = 0.01). In addition, postprandial plasma glucose concentrations after all three meals were decreased by 20% (P = 0.01, P = 0.02, and P = 0.02, respectively) during liraglutide treatment Reference Study 1332. Degn et al. Diabetes 2004;53:1187-1194 * * 作为基于GLP-1的治疗，利拉鲁肽可以显著改善胰岛素的分泌功能，下面我们一起来看看Beta细胞稳态评估模型指数： LEAD-2研究显示： 利拉鲁肽1.2mg组从基线时的47%提高至70%；利拉鲁肽1.8mg组从基线时的43%提高至71%；格列美脲4mg组从基线